Sarah Danson
University of Sheffield(GB)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cancer Genomics and Diagnostics, Immunotherapy and Immune Responses
Most-Cited Works
- → The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours(2015)635 cited
- → Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy(2015)521 cited
- → Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer(2004)385 cited
- → Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer(2004)376 cited
- → Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes(2004)278 cited
- → Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial(2021)253 cited
- → Tamoxifen (‘Nolvadex’): a review(2002)223 cited
- → Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies(2020)222 cited
- → DT-diaphorase: a target for new anticancer drugs(2004)184 cited
- → Methotrexate Is a JAK/STAT Pathway Inhibitor(2015)163 cited